



Press release from Emotra AB (publ)

Göteborg, May 7, 2020

How covid-19 is affecting Emotra's operations

Many companies in the so-called life science sector have been affected by the ongoing pandemic, and Emotra is no exception. Since Emotra is in the planning phase of projects such as clinical studies and further technical development of EDOR, we believe that the effects of the pandemic on our operations in 2020 will be limited. Given the long-term financial challenges that arise with the vast uncertainty that many people are facing in this crisis, we anticipate an increased need for novel mental-health-care solutions.

The ongoing pandemic is causing a lot of uncertainty, forcing both companies and society in general to change their plans. Naturally, these changed plans also affect Emotra's operations. We are presently focusing on two projects — clinical studies of the connection between hyporeactivity and depression relapse, and digitalisation of the test data analysis process using artificial intelligence.

The preparations for our planned clinical studies are partially affected by the fact that our clinical collaboration partners do not know when they will once again be able to receive patients for these studies. We believe that the lockdowns that have been imposed in several countries will be lightened in the near future and that the number of patients available for our studies will return to the same levels as before the pandemic broke out. Our AI project, on the other hand, is independent of access to patients or psychiatric care in general. We already have enough data to attract the right competence to the Company and will commence this work this year.

In the long term, we believe that the economic downturn and its effects on people's health will increase the need for new technology and methods in the psychiatric and psychological care sectors. We can already see an increase in the consumption of antidepressants, which should reasonably lead to more people in need of diagnostics and care plans.

For further information about Emotra, please contact:

Daniel Poté, CEO, telephone: +46 73-234 41 93, E-mail: daniel@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR®, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.